Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs)
Introduction
The metabolic syndrome affects persons with schizophrenia significantly more than the general population, a fact related to the use of atypical antipsychotics (AAPs) (McEvoy et al., 2005). The metabolic syndrome comprises a cluster of risk factors including abdominal obesity; abnormalities in glucose metabolism, dyslipidemia, and elevated blood pressure, and was associated with an increased risk of cardiovascular disease (CVD) and diabetes (DM) (Davidson, 2002). Our group, and others, have reported that occurrence of metabolic syndrome within schizophrenia is associated with pharmacogenetically regulated folate and homocysteine metabolism as well as folate exposure though dietary intake (Ellingrod et al., 2008, Garcia-Miss Mdel et al., 2010, van Winkel et al., 2010a, van Winkel et al., 2010b, Ellingrod et al., 2010). Presence of at least one variant allele for either of the key enzymes methylenetetrafolate reductase (MTHFR) 677 C/T (rs1801133), 1298A/C (rs1801131) or catechol-o-methylatransferase (COMT) 158 Val/Met (rs4680) may increase the risk of metabolic syndrome within this population due to their roles in folate and homocysteine metabolism (Ellingrod et al., 2008, Tunbridge et al., 2008). While the literature related to metabolic syndrome risk within schizophrenia is rapidly expanding and lifestyle factors such as poor diet and a high incidence of cigarette smoking have also been identified as risk factors for increased CVD within this group (Vancampfort et al., 2010, DE Hert et al., 2009, Bobes et al., 2010), much remains unknown about the pathophysiology of CVD within schizophrenia. It is known that the vascular endothelium is adversely affected by the metabolic syndrome, (Benjamin et al., 2004, McVeigh et al., 1992, Brook et al., 2001, Lupattelli et al., 2000, Kuvin et al., 2003a, Tziomalos et al., 2010), increasing the cardiovascular disease (CVD) risk.
The endothelium is a vital organ that has garnered important attention due to its relationship to CVD (Ross, 1999, Haynes, 2003, Rubinshtein et al., 2010). Physiologically the endothelium is comprised of a single layer of cells that line all blood vessels, and represents an important organ though its effects on regulating vasomotor tone, thrombosis, inflammation, platelet and leukocyte adhesion and vascular permeability (Lane et al., 2006). The presence of endothelial dysfunction increases the risk of CVD not only in individuals with established vascular disease, but also in those without (Kullo and Malik, 2007). Thus measuring endothelial functioning may help to identify those at greatest risk for CVD. Unfortunately this measure has primarily been a research tool due to the invasive nature of this assessment as well as issues related to operator dependency (Bonetti et al., 2004). However, recently, measurement of fingertip pulse amplitude tonometry (RH-PAT) has introduced a non-invasive method for measuring small vessel (arteriole) endothelial-dependent vasodilatation and determining vascular health within the ambulatory clinic setting (Bonetti et al., 2004, Kuvin et al., 2003b, Kuvin et al., 2007). Pulse amplitude hyperemic response impairment has been associated with endothelial dysfunction and abnormal RH-PAT results have been correlated with the traditional invasive assessments of arteriole endothelial-dependent vasodilatation (Bonetti et al., 2004).
The aim of this investigation was to measure arteriole endothelial-dependent vasodilatation and the extent of endothelium dysfunction within the schizophrenia population using a non-invasive method, to determine the associated pharmacogenetic, medication, dietary, and lifestyle factors. We hypothesized that the prevalence of endothelial dysfunction would be similar to the prevalence of metabolic syndrome. Additionally we also proposed that presence of poorer arteriole endothelial-dependent vasodilatation and endothelial dysfunction would be related to AAP use, dietary and lifestyle measures, and the MTHFR and COMT genetic variants that regulate folate and homocysteine metabolism.
Section snippets
Subjects
Subjects were included in this cross-sectional analysis if they meet the following inclusion criteria: 1) Presence of a DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder, 2) between the ages of 18–90 years of age, and 3) their physician determined that they should be treated with an antipsychotic which they had been receiving for at least 6 months. Subjects were excluded if they 1) were unwilling to participate, 2) lacked the ability to give informed
Statistical analysis
Subjects currently receiving olanzapine, clozapine, quetiapine, risperidone, or paliperidone were classified as receiving an atypical antipsychotic (AAP). Ziprasidone and aripiprazole were not included in this primary classification due to their lack of weight gain liability (Komossa et al., 2009a, Komossa et al., 2009b). The criteria used for endothelial dysfunction was an RH-PAT value of < 1.67 as previously discussed. Both the MTHFR and COMT variants have shown a relationship between CVD risk
Results
We analyzed a total of 83 subjects with a schizophrenia spectrum diagnosis. The mean age (± s.d.) of subjects in years was 45.89 ± 111.49 (range = 22–70 years old). The majority of subjects (64%, n = 53) were Caucasian, with 27% (n = 22) reporting to be African American. Similar to the overall demographics of schizophrenia, 64% (n = 53) of our study group was male. The mean body mass index (BMI) of subjects was 33.2 ± 7.97 and 44% (n = 36) met metabolic syndrome criterion which is in line with the previous
Discussion
Overall this investigation found that 50% of schizophrenia subjects meet criteria for endothelial dysfunction (RH-PAT < 1.67) (Bonetti et al., 2004), which is to our knowledge the first time this has been reported. Given that at least 40% of schizophrenia subjects meet metabolic syndrome criteria, and that this population is at high risk for AAP associated metabolic complications, we hypothesized that at least 40% of our group would have an RH-PAT < 1.67, similar to the incidence of metabolic
Limitations
Despite our best research efforts this investigation has some limitations. Most notably this is a cross-sectional study that only had one assessment for the arteriole endothelial-dependent vasodilatation. Additionally lack of a specific control may limit our results and the use of the 24 h food recount for quantifying an average daily intake is not optimal, despite our use of this assessment in triplicate in an effort to obtain a good approximation of each subject's usual diet. Lack of blood
Summary
In summary, as part of this investigation we found that 50% of individuals with schizophrenia met the criteria for endothelial dysfunction when measured using the non-invasive EndoPAT2000. This percentage is similar to the 40% incidence of metabolic syndrome seen in this population. This investigation is the first, to our knowledge, to report on the prevalance of endothelial dysfunction (RH-PAT < 1.67) within the schizophrenia population. Additionally we found an interaction between total dietary
Funding sources and roles
This project was supported by the NIMH (R01 MH082784-01) and the NIH-NCCR, GCRC Program (M01-RR-59 and UL1RR024986), the Chemistry Core of the Michigan Diabetes Research and Training Center (NIH5P60 DK 20572), and the Washtenaw Community Health Organization (WCHO). None of these funding and support agencies had any further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Contributors
Authors Ellingrod, Taylor, Zoellner, Brook, Dalack and Pop-Busui designed the study and wrote the protocol. Authors Ellingrod, Evans, Grove, and Bly managed the literature searches and analyses. Authors Ellingrod and Zöllner undertook the statistical analysis, and author Ellingrod wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.
Conflict of interest
The authors have no conflicts of interest to disclose.
Acknowledgments
We wish to thank all of the study participants.
References (54)
- et al.
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort
Schizophr. Res.
(2010) - et al.
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia
J. Am. Coll. Cardiol.
(2004) - et al.
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults
Am. J. Cardiol.
(2001) - et al.
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677 C/T and 1298A/C variants
Schizophr. Res.
(2008) - et al.
Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment
Prostaglandins Leukot. Essent. Fatty Acids
(2003) - et al.
Effect of long-term hormone replacement therapy on coronary endothelial function in postmenopausal women
Mayo Clin. Proc.
(2004) - et al.
Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification
J. Am. Coll. Cardiol.
(2007) - et al.
Relation between high-density lipoprotein cholesterol and peripheral vasomotor function
Am. J. Cardiol.
(2003) - et al.
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude
Am. Heart J.
(2003) - et al.
Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles
Am. Heart J.
(2000)
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
Schizophr. Res.
Relationship between the niacin skin flush response and essential fatty acids in schizophrenia
Prostaglandins Leukot. Essent. Fatty Acids
Smoking and endothelial function
Prog. Cardiovasc. Dis.
Maintaining a nutrient database in a changing marketplace: keeping pace with changing food products — a research perspective
J. Food Composition Analysis.
Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management
Nutr. Metab. Cardiovasc. Dis.
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
Psychiatry Res.
Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial
Arch. Gen. Psychiatry
Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study
Circulation
Endothelial dysfunction: a marker of atherosclerotic risk
Arterioscler. Thromb. Vasc. Biol.
Cancer incidence in patients with schizophrenia and their first-degree relatives — a meta-analysis
Acta Psychiatr. Scand.
A symposium: National Cholesterol Education Program Adult Treatment Panel III: impact and implementation of the new guidelines. Introduction
Am. J. Cardiol.
Metabolic syndrome in people with schizophrenia: a review
World Psychiatry.
Methylenetetrahydrofolate reductase (MTHFR) 677 C/T and Catechol-O-Methyltransferase (COMT) Val158Met variants and endothelial functioning in schizophrenia and bipolar subjects treated with antipsychotics
J. Pharm. Pract.
Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia
J. Psychiatr. Res.
Folate, homocysteine, and negative symptoms in schizophrenia
Am. J. Psychiatry
Peripheral arterial tonometry: a diagnostic method for detection of myocardial ischemia induced during mental stress tests: a pilot study
Clin. Cardiol.
Oxidative Stress and Endothelial Dysfunction: Say No to Cigarette Smoking!
Cited by (33)
A role for endothelial NMDA receptors in the pathophysiology of schizophrenia
2022, Schizophrenia ResearchCitation Excerpt :Specifically, the NOS3 rs2070744 variant has been linked to schizophrenia (Fattakhov et al., 2018); this mutation occurs in the promoter region of the NOS3 gene, consequently reducing eNOS mRNA levels (Miyamoto et al., 2000). Schizophrenia patients who are carriers of this variant are found to have a significant decreases in peripheral vasodilation (Burghardt et al., 2014; Ellingrod et al., 2011; Israel et al., 2011; Najjar et al., 2017). d-Serine has emerged as a potential adjunctive therapy for schizophrenia (Kantrowitz et al., 2010), as well as a biomarker; lower levels of d-serine have been reported in cerebrospinal fluid and from blood of schizophrenia patients (for a review, see (MacKay et al., 2019)).
Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study
2022, Schizophrenia ResearchCitation Excerpt :About 60 % of the excess mortality observed in patients suffering from psychosis is due to physical co-morbidities, predominantly cardiovascular diseases (Vancampfort et al., 2015). Schizophrenia patients have a significantly higher risk of presenting metabolic disturbances such as abdominal obesity, type 2 diabetes mellitus (T2DM), arterial hypertension, low high-density lipoprotein cholesterol (HDLC), hypertriglyceridemia and reduced arterial compliance and endothelial dysfunction (Vancampfort et al., 2013) (Ellingrod et al., 2011; Koola et al., 2012), explaining their higher cardiovascular risk (CVR) than the observed in the general population. Recent studies support that these metabolic disturbances are present from the early phases of the psychosis (Pillinger et al., 2017), increasing with illness duration of schizophrenia (Carney et al., 2016) and with age (Emul and Kalelioglu, 2015).
Detrimental effects of chemotherapeutics and other drugs on the endothelium: A call for endothelial toxicity profiling
2015, Pharmacological ReportsCitation Excerpt :This set of experiments supports the notion that antipsychotic agents induce endothelial dysfunction, which could contribute to their metabolic side effects. Surprisingly, using fingertip pulse amplitude tonometry (RH-PAT) detrimental effects of atypical antipsychotic (clozapine, olanzapine, paliperidone, risperidone, quetiapine) on post occlusion reactive hyperaemia were not confirmed [56]. If the obesity-inducing APs’ activity is mediated through an endothelial mechanism, this should be visible in the RH-PAT examination.
Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders
2015, Schizophrenia ResearchCitation Excerpt :Previous reports show that two-thirds of people with schizophrenia are diagnosed with CVD, compared to one-half of the general population, and this high rate of CVD morbidity is directly related to decreased life expectancy in schizophrenia (Hennekens et al., 2005; Fan et al., 2013). One potential mechanism for the development of CVD may be found within enzymes responsible for the metabolism of folate, methylenetetrahydrofolate reductase (MTHFR) C677T and catechol-O-methyltransferase (COMT) Val158Met, as variant or risk alleles (MTHFR T and COMT Val alleles) are linked to CVD risk in schizophrenia (Kullo and Malik, 2007; Ellingrod et al., 2011; Burghardt and Ellingrod, 2013). Additionally, MTHFR and COMT risk alleles are associated with reduced prefrontal cortex functioning and neurocognitive deficits in schizophrenia (Roffman et al., 2007, 2008a,b, 2011a,b).
Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism
2014, Journal of Psychiatric ResearchSelection, Use and Psychometric Properties of Physical Activity Measures to Assess Individuals with Severe Mental Illness: A Narrative Synthesis
2014, Archives of Psychiatric NursingCitation Excerpt :One major problem of studies measuring physical activity is the failure of researchers to consider or justify why they have chosen a particular OBM or SRQ. For example past research studies (Archie et al., 2007; Brill et al., 2007; Buhagiar et al., 2011; Chuang et al., 2008; Crone et al., 2004; Daumit et al., 2005; Davidson et al., 1999; Davidson et al., 2001; Ellingrod et al., 2011; Elmslie et al., 2001; Farnam et al., 1999; Lassenigus et al., 2013; McCreadie, 2003; Osborn et al., 2007; Ratliff et al., 2012; Samele et al., 2007; SØrensen, 2006; Van Citters et al., 2010; Vancampfort et al., 2011a,b,c; Vancampfort et al. (2011d) have utilised a specific SRQ and justified its choice solely on the original study which validated the SRQ. This is often problematic if the tool has been validated in a certain population or if the original study was not validated correctly.